ENTRY       D10513            Mixture   Drug
NAME        Clopidogrel sulfate and aspirin;
            Clopidogrel and acetylsalicyclic acid;
            Complavin (TN)
COMPONENT   (Clopidogrel sulfate [DR:D00769] | Clopidogrel [DR:D07729]), Aspirin [DR:D00109]
CLASS       Metabolizing enzyme substrate
             DG01892  CYP1A2 substrate
             DG02919  CYP2B6 substrate
             DG01639  CYP2C19 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
            Metabolizing enzyme inhibitor
             DG01641  CYP2C8 inhibitor
REMARK      Therapeutic category: 3399
            ATC code: B01AC30
            Product: D10513<JP>
EFFICACY    Antiplatelet
COMMENT     Clopidogrel is metabolized to an active metabolite mainly by CYP2C19, and CYP1A2, CYP2B6 and CYP3A4 contribute to the generation of the active metabolite, and Clopidogrel glucuronate conjugate is an inhibitor of CYP2C8.
METABOLISM  Enzyme: CYP2C19 [HSA:1557]; CYP1A2 [HSA:1544], CYP2B6 [HSA:1555], CYP3A4 [HSA:1576]
INTERACTION CYP inhibition: CYP2C8 [HSA:1558]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             B BLOOD AND BLOOD FORMING ORGANS
              B01 ANTITHROMBOTIC AGENTS
               B01A ANTITHROMBOTIC AGENTS
                B01AC Platelet aggregation inhibitors excl. heparin
                 B01AC30 Combinations
                  D10513  Clopidogrel sulfate and aspirin &lt;JP&gt;
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              33  Blood and body fluid agents
               339  Miscellaneous
                3399  Others
                 D10513  Clopidogrel sulfate and aspirin
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG01892  CYP1A2 substrate
               D10513  Clopidogrel sulfate and aspirin
              DG02919  CYP2B6 substrate
               D10513  Clopidogrel sulfate and aspirin
              DG01639  CYP2C19 substrate
               D10513  Clopidogrel sulfate and aspirin
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D10513  Clopidogrel sulfate and aspirin
             Metabolizing enzyme inhibitor
              DG01641  CYP2C8 inhibitor
               D10513  Clopidogrel sulfate and aspirin
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10513
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10513
DBLINKS     PubChem: 172232606
///
